September 8, 2025 7:45am

… Inflation data, what will be the color of the week red or green; with time to “shade” your portfolio’s stress from inflation data and Fed’s upcoming policy meeting

News: Pfizer (PFE) and BioNTech SE (BNTX -$0.72) positive topline results from an ongoing P3 clinical trial cohort evaluating the safety, tolerability, and immunogenicity of a 30-µg dose of the LP.8.1-adapted monovalent COMIRNATY® (COVID-19 Vaccine, mRNA) 2025-2026 Formula in adults aged 65 and older and in adults aged 18 through 64 with at least one underlying risk condition for severe COVID-19. <more below>

Never leave an investor uninformed … I say what others won’t, so you can do what others can’t!

The cell and gene therapy sector has seen a few too many fits and starts, so …

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

 

Friday’s night’s … RMi) Closing Bell: An index rally dissolved while the cell and gene therapy sector boomed … https://www.regmedinvestors.com/articles/14094

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB): Just another wrinkle – Q2/25’s 10-Q – liabilities exceed cash position … https://www.regmedinvestors.com/articles/13812

 

Monday: The pre-open Dow futures are UP +0.15% or (+67 points), the S&P futures are UP +0.23% or (+15 points) and the Nasdaq futures are UP +0.38% or (+89 points)

  • Stock futures ticked higher on Monday, 9/8
  • European stocks opened on a positive note,
  • Asia-Pacific markets traded mostly higher.

 

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

  • Friday: The Dow closed DOWN -220.43 points or -0.48%, the S&P closed DOWN -20.58 points or -0.32% while the Nasdaq closed DOWN -7.306 points or -0.03%
  • Thursday: The Dow closed UP +350.06 points or +0.77%, the S&P closed UP +53.82 points or +0.83% while the Nasdaq closed UP +209.968 points or +0.98%
  • Wednesday: The Dow closed DOWN -24.95 points or -0.06%, the S&P closed UP +32.74 points or +0.51% while the Nasdaq closed UP +218.097 points or +1.03%
  • Tuesday: The Dow closed DOWN -249.07 points or -0.55%, the S&P closed DOWN -44.72 points or -0.69% while the Nasdaq closed DOWN – 175.922 points or -0.82%
  • Monday closed for the Labor Day holiday, global markets did remain open
  • Last week, the Dow was lost -0.32%, the S&P 500 +0.33% and Nasdaq gained +1.14%.

Economic Data Docket: Consumer credit

  • In the week, Wednesday’s PPI and wholesale inventories and Fed Chair Powell’s press conference at 2:30 p.m., ET, Thursday's CPI (inflation data) initial jobless claims, the weekly update on mortgage rates will be closely watched. Friday’s consumer sentiment could offer uncertain mix of upcoming inflation pressures; followed by None on Friday – Thankfully.

 

Pfizer (PFE) and BioNTech SE (BNTX) positive topline results (continued):

  • The preliminary data show a robust increase in neutralizing antibodies targeting the LP.8.1 sub-lineage of SARS-CoV-2 following vaccination.
  • These clinical findings reinforce pre-clinical data that supported the recent FDA approval of the LP.8.1-adapted COVID-19 vaccine, which demonstrated improved immune responses against multiple circulating SARS-CoV-2 sub-lineages.
  • A total of 100 participants were enrolled in the open-label P3 trial cohort, 50 adults aged 65 and older and 50 adults aged 18-64 with at least one underlying risk condition for severe COVID-19.
  • Prior to receiving the LP.8.1-adapted COVID-19 vaccine 2025-2026 Formula, all participants had received the KP.2-adapted COVID-19 vaccine at least six months prior to enrollment and had not received any other COVID-19 vaccine or had COVID-19 disease since the KP.2 vaccination through enrollment in the study.
  • Data from evaluable participants showed that the LP.8.1-adapted COVID-19 vaccine elicited a robust immune response against the LP.8.1 sub-lineage.
  • In both age groups, 14 days following vaccination, LP.8.1-neutralizing antibody titers exceeded pre-vaccination levels, on average, by at least 4-fold.
  • The safety profile of the vaccine was consistent with previous studies, with no new safety concerns identified.

 

Q3 – September, 1 holiday, 1 negative and 3 positive closes

  • August - 11 negative and 9 positive closes
  • July – 1 market holiday, 13 positive and 9 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

  • Let ‘em ride, I see a “muddy” week on Monday yet, green after the muddle of red lead  into September, along with the usual ups, downs and just plain uncertainties

 

The BOTTOM LINE: Econs matter in “this” market scenario; brace for inflation data this week amid emerging labor market cracks …

Stocks vacillated Friday, with the major averages falling during midday trading after making a move to all-time highs earlier in the day. <CNBC>

  • Those moves follow the latest nonfarm payrolls report, which confirmed what many investors were already anticipating:
  • The labor market has taken a turn for the worse, and is now in a downtrend.
  • The good news is that an interest rate cut is virtually guaranteed at the next Fed meeting less than 2 weeks away.
  • Will a supersized rate cut is at play.
  • The bad news: The economy appears to be weakening.

September is historically the worst month for equities …

  • Are tariffs more of an issue to the future, hope the Supreme Courts levels over-reaching state/federal courts?
  • Don’t forget about Fed governor Lisa Cook and her “mortgage fraud criminal referral to DOJ>issues of being fired or not?

 

September is in the front window: understand the “flow”

  • 9/5 – Friday closed positive with 35 positive, 5 negative and 0 flat
  • 9/4 – Thursday closed negative with 17 positive, 21 negative and 2 flats of the 40 covered
  • 9/3 – Wednesday closed positive with 22 positive, 16 negative and 2 flats
  • 9/2 -Tuesday closed positive with 22 positive, 18 negative and 0 flat
  • 9/1 -Monday was a holiday

The last week of August:

  • 8/29 – Friday closed negative with 7 positive, 27 negative and 1 flat of the 35 covered
  • 8/28 – Thursday closed negative with 15 positive, 17 negative and 3 flats
  • 8/27 – Wednesday closed negative with 16 positive, 17 negative and 2 flats
  • 8/26 - Tuesday closed positive with 25 positive, 9 negative and 1 flat
  • 8/25 – Monday closed negative with 4 positive, 29 negative and 2 flats

 

Earnings are in rhe rear view: 

  • Earnings:  4 net incomes and 25 net losses of 29 releases to date

I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

Welcome to my world of defining the “grey’ in our universe!

  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

 I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.